Author

G. Villacampa

h-index 31 View on Semantic Scholar

We have 3 of 269 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer

Findings show that resistance to ICI in liver metastases arises from tissue-specific misdirection of immune activation away from productive antitumor immunity, identifying multicellular coordination of the immune response in the metastatic microenvironment as a determinant of therapeutic efficacy.

I. Baraibar, S. Morabito, G. Deuner-Cos et al. · medRxiv · 0 citations

Review Sep 2026

Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer.

BACKGROUND One-third of patients with triple-negative breast cancer (TNBC) are diagnosed with stage I tumors. Biomarkers to stratify prognosis in this setting remain a major unmet need. METHODS Tissue samples and clinicopathologic data were retrieved from consecutive patients with stage I TNBC (defined as ER <10% and...

P. Tarantino, Tian-Yu Li, Laia Paré Brunet et al. · European Journal of Cancer · 0 citations

Open access Jul 2026

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer

BRCA2 PVs were independently associated with poorer outcomes to first-line CDK4/6i plus ET in HR-positive/HER2-negative MBC compared with controls, especially relevant among patients with endocrine-sensitive disease.

M. Cruellas, A. Rodriguez-Hernandez, L. Carità et al. · ESMO Open · 0 citations